An interventional study of IPL/Lipiflow and IPL/MGX in Meibomian Gland Dysfunction, sponsored by Aier School of Ophthalmology, Central South University. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Aier School of Ophthalmology, Central South University · Not applicable, Interventional, and Treatment
To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland massage in treating meibomian gland dysfunction of different degrees ,focusing on effective rate, lasting time and changes of meibomian gland function and morphology.
To divide all participants into two groups, group one treated with IPL combined with Lipiflow and group two treated with IPL combined with meibomian gland massage.The following parameters were recorded after treatment: the effective rate, lasting time and changes of meibomian gland function and morphology.All parameters were compared between the two groups.
172 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 138 interventional studies indexed under Meibomian Gland Dysfunction.
Browse Meibomian Gland Dysfunction studies →Aier School of Ophthalmology, Central South University is the lead sponsor of 18 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
the group in which patients treated with IPL combined with lipiflow
Procedure: IPL/Lipiflow
the group in which patients treated with IPL combined with meibomian gland massage
Procedure: IPL/MGX
To treat patients with MGD using intense pulsed light combined with lipiflow
To treat patients with MGD using intense pulsed light combined with meibomian gland massage
ocular surface disease index(OSDI)
The OSDI is assessed on a scale of 0 to 100,with higher scores representing greater disability
Time frame: 6 months
meibomian gland expressibility score and meibum quality score
The score is on a scale of 0 to 6.The higher scores, the severity of the meibomian gland function(the highest score is 6 and the lowest score is 0)
Time frame: 6 months
meibomian gland dropout score
the higher scores, the severity of the meibomian gland morphology(The highest score is 6 and the lowest score is 0)
Time frame: 6 months
Breakup time
the shorter time, the poorer of the tear film stability
Time frame: 6 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2020; primary completion for Dec 2020, 0 months later.
Of 52 non-industry interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 0 months is below that.
Counting every sponsor, half of 74 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aier School of Ophthalmology, Central South University